## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Single Technology Appraisal**

# Nalmefene for reducing alcohol consumption in people with alcohol dependence [ID660]

## **Matrix of consultees and commentators**

Consultees	Commentators (no right to submit or appeal)
	аррош)
Manufacturers/sponsors	General
Lundbeck (nalmefene)	Allied Health Professionals Federation
	Board of Community Health Councils in
Patient/carer groups	Wales
Action on Addiction     Add a stick	British National Formulary
Addaction     Addiction Today	Care Council for Wales
Addiction Today	Care Quality Commission
ADFAM     Afive Trust	Commissioning Support Appraisals     Service
<ul><li>Afiya Trust</li><li>Al-Anon</li></ul>	
<ul><li>Al-Anon</li><li>Alcohol Concern</li></ul>	<ul> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> </ul>
Alcoholics Anonymous (AA)	Healthcare Improvement Scotland
Black Health Agency	Medicines and Healthcare products
British Liver Trust	Regulatory Agency
Compass UK	National Association of Primary Care
• CRI	National Pharmacy Association
Equalities National Council	NHS Alliance
Lifeline Project	NHS Commercial Medicines Unit
Muslim Council of Britain	NHS Confederation
Muslim Health Network	Scottish Medicines Consortium
National Association for Children of	Social Care Institute for Excellence
Alcoholics	
<ul> <li>Rehabilitation for Addicted Prisoners</li> </ul>	Comparator manufacturers
Trust (RAPt)	Accord Healthcare (Naltrexone)
South Asian Health Foundation	AOP Orphan Pharmaceuticals AG
Specialised Healthcare Alliance	(Adepend)
Turning Point	<ul> <li>Bristol-Myers Squibb Pharmaceuticals (Nalorex)</li> </ul>
Professional groups	Genus Pharmaceuticals (Opizone)
British Association for Counselling and	
Psychotherapy	Relevant research groups
British Association for	Alcohol Research UK
Psychopharmacology	Campbell Collaboration Social Welfare
British Association for Social Workers	Group
British Association for the Study of the	Drink Aware

National Institute for Health and Care Excellence

Matrix for the technology appraisal of nalmefene for reducing alcohol consumption in people with alcohol dependence [ID660]

Issue date: January 2014 Page 1 of 4

#### Consultees Commentators (no right to submit or appeal) Liver Foundation for Liver Research British Association for the Study of the Health Research Authority Liver Nurses Forum Institute of Alcohol Study British Association of Behavioural and Institute of Psychiatry Cognitive Psychotherapies Joseph Rowntree Foundation • British Confederation of MRC Clinical Trials Unit **Psychotherapists** National Institute for Health Research British Geriatrics Society National Primary Care Research & British Liver Nurses Forum **Development Centre** British Neuropsychiatry Association Research Institute for the Care of Older British Psychological Society People British Psychotherapy Foundation British Society of Gastroenterology **Evidence Review Group** College of Mental Health Pharmacy School of Health and Related College of Occupational Therapists Research (ScHARR) National Institute for Health Research Counsellors and Psychotherapists in Health Technology Assessment **Primary Care** Programme Health and Care Professions Council (formerly General Social Care Associated Guideline groups Council) National Collaborating Centre for Mental Health Nurses Association Mental Health (formerly Community Psychiatric Nurses Association) Associated Public Health groups National Substance Misuse Non-Alcohol-use disorders: Preventing Medical Prescribing Forum harmful drinking - Programme Royal College of General Practitioners **Development Group** Royal College of Nursing • Local Government Association Royal College of Pathologists Public Health England Royal College of Physicians Public Health Wales NHS Trust Royal College of Psychiatrists Royal Pharmaceutical Society Royal Society of Medicine Substance Misuse in General Practice United Kingdom Clinical Pharmacy Association United Kingdom Council for Psychotherapy Others Department of Health NHS England NHS Stafford and Surrounds CCG NHS Warrington CCG Welsh Government

National Institute for Health and Care Excellence

Matrix for the technology appraisal of nalmefene for reducing alcohol consumption in people with alcohol dependence [ID660]

Issue date: January 2014 Page 2 of 4

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: January 2014 Page 3 of 4

#### **Definitions:**

## **Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

## **Evidence Review Group (ERG)**

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Care Excellence Matrix for the technology appraisal of nalmefene for reducing alcohol consumption in people with alcohol dependence [ID660]

Issue date: January 2014 Page 4 of 4

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.